[Skip to Content]
[Skip to Content Landing]
March 2, 1984

Sclerotherapy continues to undergo evaluation

JAMA. 1984;251(9):1133. doi:10.1001/jama.1984.03340330009004

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Findings from the first prospective, controlled study of chronic esophageal sclerotherapy from the United States have become available. Jacob Korula, MD, assistant professor of medicine at the University of Southern California (USC) School of Medicine, Los Angeles, reported at the recent meeting of the American Association for the Study of Liver Diseases in Chicago that sclerotherapy "appears to decrease bleeding risk and transfusion requirements, and to prolong the bleeding-free interval," but it doesn't appear to increase survival.

According to Korula, only one other prospective, fully controlled study of intravariceal sclerotherapy has emerged from the field. That one was done in England (Lancet 1982;1:124-127). In this country, the treatment has been studied intensely only for the last four to five years.

At the time of the meeting, Korula and co-workers at USC's liver unit, Rancho Los Amigos Hospital, Downey, Calif, had treated 120 patients who had portal hypertension: 63 were randomized